Achieve Life Sciences (ACHV)

• Market cap: $157M
• 1 day: 1.32%
• 5 days: -0.65%
• 1 month: 15.79%
• 3 months: -0.65%
• 6 months: 5.84%
• Year to date: -16.53%
• 1 year: -30.47%
• 5 years: -69.14%
• 10 years: -99.94%
• Sector: Healthcare
• Industry: Biotechnology

About: Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.

Employees: 25

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

411% more call options, than puts

Call options by funds: $480K | Put options by funds: $94K

54% more capital invested

Capital invested by funds: $38.4M [Q1] → $59.3M (+$20.9M) [Q2]

40% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 15

34.13% more ownership

Funds ownership: 41.48% [Q1] → 75.61% (+34.13%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

11% less funds holding

Funds holding: 72 [Q1] → 64 (-8) [Q2]

31% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 26

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $12
• Avg. target: $12
• High target: $12

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Brandon Folkes

$12

Buy Initiated

21 Aug 2025